In an effort to give timely notice to the pharmacy community concerning important pharmacy topics, the Maryland Department of Health (MDH), Maryland Medicaid Pharmacy Program (MMPP) has developed the Maryland Medicaid Pharmacy Program Advisory. To expedite information timely to the pharmacy and prescriber communities, an email network has been established which incorporates the email lists of the Maryland Pharmacists Association, EPIC, CARE, Long Term Care Consultants, headquarters of all chain drugstores and prescriber associations and organizations. It is our hope that the information is disseminated to all interested parties. If you have not received this email through any of the previously noted parties or via MDH, please contact the MMPP representative at 410-767-1455.

**Suboxone® Film and its generic (buprenorphine and naloxone) are Preferred on the Maryland Medicaid Preferred Drug List**

The Maryland Medicaid Pharmacy Program (MMPP) wants to alert you that effective Wednesday, June 27, 2018, the following changes have occurred in the brand vs generic (DAW 6) drug program.

Due to a limited supply of generic Suboxone® Film (buprenorphine and naloxone film), **MMPP will cover both brand Suboxone® Film and its generic, buprenorphine and naloxone film.** Claims for the brand Suboxone® Film must be submitted with DAW 6 and will be priced appropriately. Claims for brand Suboxone® Film with any other DAW code will reject. A MDH MedWatch form will not be required.

If any problems are encountered during the online claim adjudication, contact Conduent 24-hour Help Desk at 800-932-3918 for additional system overrides related to the use of the correct DAW code (for example, if there is other primary insurance).

Please refer to our website for a complete list of the PDL at the following link:  

The PDL is also available on your desktop computer by accessing Formulary Navigator™ at www.mmppi.com